Albert Einstein College of Medicine marked a major milestone in aging research on April 10, 2026, with the opening of the Batia and Idan Ofer Program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL). The event brought together institutional leaders, scientists, and supporters to celebrate a significant investment in advancing the development of drugs that target aging.
“The Idan and Batia Ofer Family Foundation supports initiatives that drive meaningful long-term impact across the globe, including significant investments in medical research and patient care,” said Yaron Tomer, M.D., the Marilyn and Stanley M. Katz Dean at Einstein. “In partnering with Einstein, Idan and Batia Ofer have helped bring this vision to life, and its impact will be felt far beyond today.”
We are creating the infrastructure, the partnerships, and the momentum needed to move discoveries into clinical applications faster and more effectively than ever before. That’s the essence of BIO-VITAL—translating discoveries into patient care.
—Dr. Yaron Tomer
Funded by Idan and Batia Ofer through their family foundation, BIO-VITAL is designed to accelerate the translation of scientific discoveries into therapies, bridging the gap between laboratory science and clinical application. The Ofers attended the event along with their son, Sammy Ofer, reflecting their strong commitment to health initiatives around the globe.
“With BIO-VITAL, we are not only continuing our work in aging research; we are also transforming and accelerating it,” Dr. Tomer said. “We are creating the infrastructure, the partnerships, and the momentum needed to move discoveries into clinical applications faster and more effectively than ever before. That’s the essence of BIO-VITAL—translating discoveries into patient care.”
From left, Mr. Spodek, Mrs. Ofer, and Ph.D. student Todd Richmann in Dr. Huffman's lab.
Mr. Ofer looks in a microscope in a BIO-VITAL lab.
The day began in the dean’s conference room with a scientific overview outlining the program’s goals from Nir Barzilai, M.D., a professor of medicine and of genetics and co-director of Einstein’s Institute for Geroscience, and his fellow co-directors Ana Maria Cuervo, M.D., Ph.D., a distinguished professor of developmental & molecular biology and of medicine, and Derek M. Huffman, Ph.D., a professor of molecular pharmacology and of medicine at Einstein.
Ana Maria Cuervo, M.D., Ph.D., co-director, BIO-VITAL, presents her research to Dr. Tomer, left, the Ofers, and invited guests.
Guests also toured the labs of Drs. Cuervo and Huffman, gaining firsthand knowledge of the pioneering work being done there. BIO-VITAL integrates research across molecular, cellular, organismal, and human levels to better understand aging and identify interventions to delay or prevent age-related diseases.
The celebration culminated with a public ceremony on Main Street in the Forchheimer Building, where the BIO-VITAL sign was revealed and institutional leaders and supporters gave remarks. “What makes this moment especially meaningful is what it represents—the coming together of science, philanthropy, and purpose,” Dr. Tomer said. “It reflects a shared belief that we can do more than extend life. We can improve how people live those years.”
From left, Dr. Barzilai, Dr. Cuervo, and Dr. Huffman, co-directors of BIO-VITAL.
Mrs. Ofer addresses the crowd at the BIO-VITAL opening.
Mrs. Ofer emphasized the broader impact of the initiative. “Aging is one of the most profound challenges facing humanity,” she said. “It is our hope that BIO-VITAL will be at the forefront of aging research for years to come, fostering breakthroughs that will redefine what is possible in human health and longevity,” she said.
